Basilea has announced that it has received a further significant funding tranche of $13.3m to fund the development of the Phase 3-ready combination antibiotic ceftibuten-ledaborbactam. This brings the total BARDA funding received to date for this programme to $25m, with the existing BARDA contract potentially providing an additional $133m in non-dilutive funding. Securing non-dilutive funding has been a rewarding characteristic of Basilea's anti-infective research & development efforts. This...

Basilea announced this morning that it has been awarded additional non-dilutive funding of $6m from CARB-X for BAL2420 to fund the ongoing first-in-man Phase 1 study. BAL2420 has previously been supported by CARB-X funding, including $7.5m in 2024, as the programme moved towards the clinic. Overall we believe that the support from CARB-X represents a strong endorsement of this particular approach given CARB-X's focus on accelerating programmes targeting the WHO and CDC's Priority Pathogens...

Basilea announced this morning that its novel antibiotic to treat problematic Gram-negative infections has moved into first-in-human clinical studies. BAL2420 is targeting the lipopolysaccharide (LPS) transport bridge which helps maintain the integrity of the outer membrane in Gram-negative bacteria. Targeting LPS production and its transport machinery has already proven to be a productive approach in the development of antibiotics targeting the outer membrane of Gram-negative bacteria....